ASGCT Annual Meeting 2023 – Los Angeles, California

May 16-20, 2023

Taking cell and gene therapies from medicine to market requires global expertise, technical capabilities, and a strategic partner you can trust. Schedule a meeting with us at the ASGCT 26th Annual Meeting to learn how we can support you as your trusted partner through your drug development journey.

About ASGCT Annual Meeting

The American Society of Gene Cell Therapy (ASGCT) Annual Meeting is the premier event for professionals in the advanced therapies field. Attendees will have the opportunity to listen to thought-provoking content from high-profile speakers and participate in unparalleled networking events.

Join us at the event where our CDMO services experts will be at booth #235 to discuss how our expertise, capacity, and global network can address your project’s unique needs. We will also be featuring our cell and gene therapy (CGT) products – connected from development to delivery – including Translational Services, Development, and GMP manufacturing services. This includes Plasmid DNA, Viral Vectors, Cell Therapy, and mRNA, as well as our supply chain solutions.

We look forward to seeing you at the event and invite you to schedule a private meeting with us to discuss how we can support you as your trusted partner.


Lunch symposium

We will be hosting a lunch symposium on Thursday, May 18th from 12pm to 1:30pm PDT. This symposium explore the potential of AAV-based gene therapy, as well as advances and challenges in the field. There will be a combination of presentations as well as a panel discussion regarding Thermo Fisher Scientific’s complete product and service offering, designed to streamline the journey from the bench to the clinic, and ensure the delivery of high-quality final products.

Our experts will also be available to meet with you at this event. Click on the link above if you’re interested in scheduling a meeting.


Event details 

Date: May 16-20, 2023

Format: In-person

Location: Los Angeles Convention Center, Los Angeles, California

Booth Number: #235

Event Website:



Samira Shore,
Director, Technical Program Design
Viral Vector Services
Thermo Fisher Scientific

Samira Shire

Samira is the Director of Technical Program Design for Viral Vector Services at Thermo Fisher Scientific. Samira oversees Viral Vector program design team - providing technical knowledge and strategic support - enabling customers to achieve their clinical and commercial goals

Samira's career in the CDMO industry spans over ten years, with expertise focused on development and manufacturing of monoclonal antibodies, small molecules, and viral vectors. She has a strong background in process development and scale up, and is experienced with general regulatory requirements for gene therapies.



Elizabeth Woo (Betty), Ph.D.
Vice President, Cell, Gene, and Advanced Therapies
Thermo Fisher Scientific

Betty Woo

Betty currently serves as Vice President of Cell, Gene, and Advanced Therapies, spanning biosciences, bioproduction, and laboratory products businesses across Thermo Fisher Scientific, leveraging “total company” to address the needs of developers and manufacturers of cell and gene therapies. The business focuses on fit-for-purpose product solutions that in partnership with our customers, is increasing the accessibility of these life-changing cell and gene therapies to patients.

Prior to this role, she formed and led a corporate team focused on scientific collaborations with Thermo Fisher strategic customers, as Vice President, Enterprise Science & Innovation (2018-2020), and served as VP of Corporate Accounts with responsibility for cultivating executive relationships with global biopharma (2009-2017). Prior to her corporate roles, Betty served in leadership roles in Fisher Scientific, including Industry Vice President, Biotechnology (2004-2008);



Jon Zmuda, Ph.D.
Director, Cell Biology R&D
Biosciences Division
Thermo Fisher Scientific

Jon Zmuda

Jonathan Zmuda, Ph.D. is a Director of Cell Biology R&D within the Biosciences Division of Thermo Fisher Scientific located in Frederick, MD (USA). Within Cell Biology, Jon leads various teams that focus on developing new technologies for protein expression, viral vector production, transfection and classical cell culture.

Dr. Zmuda received his Ph.D. in Cell Biology from the University of Maryland, College Park and his undergraduate degree from Dickinson College in Carlisle, PA.



Adam Miller,
Upstream Process Development,
Encoded Therapeutics

Adam Miller

Adam Miller serves as Director of Upstream Process Development at Encoded Therapeutics, where he has successfully established a best-in-class rAAV expression platform. He has a proven track record of establishing Upstream Process Development capabilities at multiple biotechnology companies and has played a pivotal role in advancing numerous programs from early R&D to clinical manufacturing.

Adam holds a B.S. in Biochemistry, Cell, and Molecular Biology from Drake University. He further studied Bioprocessing at Keck Graduate Institute, where he earned a Master of Bioscience (MBS) degree.


Continuing education for the pharma industry 


Follow us on social for event updates

We look forward to seeing you soon